Parallax Volatility Advisers
PETX

Parallax Volatility Advisers’s Aratana Therapeutics, Inc. PETX Stock Holding History

Parallax Volatility Advisers’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,216
Closed -$33K – 5090
2017
Q4 		$33K Buy
+6,216
New +$38K ﹤0.01% 3449

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallax Volatility Advisers's PETX Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 6,216 shares — an estimated $33K sold.

Parallax Volatility Advisers first reported a position in PETX in Q4 2017 and held it in 1 quarter. The position peaked at $33K in Q4 2017. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 6,216 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $33K.
  • Parallax Volatility Advisers first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Aratana Therapeutics, Inc. position peaked at $33K in Q4 2017.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.